Glenmark Generics Inc., USA (GGI) the subsidiary of Glenmark Generics has been granted final approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration (USFDA) for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.
Omeprazole DR Capsules are indicated for the short-term treatment of active duodenal ulcer in adults. The approval is for the 10, 20, and 40mg strengths of Omeprazole. According to IMS Health sales data for the 12 month period ending September 2014, Omeprazole garnered annual sales of approximately $520 million.
Glenmark’s current portfolio consists of 94 products authorized for distribution in the US marketplace and 72 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: